Patients with the ER-negative/PR-negative subtype had a 7% higher risk of BC-specific death (HR, 1.07; 95% CI, 1.03-1.11) than those with the ER-negative/PR-positive subtype. The gene discussed is ESR1; the disease is breast cancer.